PT - JOURNAL ARTICLE AU - Lu, Chenggang AU - Xie, Yongping AU - Li, Yan AU - Cheng, Fangfang AU - Huang, Lisu AU - Hua, Wang TI - Analysis of clinical characteristics of invasive non-typhoidal <em>Salmonella</em> infections in children: a 5-year dual-center retrospective study AID - 10.1101/2024.10.03.24314827 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.03.24314827 4099 - http://medrxiv.org/content/early/2024/10/04/2024.10.03.24314827.short 4100 - http://medrxiv.org/content/early/2024/10/04/2024.10.03.24314827.full AB - Objective To investigate the incidence, microbiological characteristics, clinical manifestations, and antibiotic resistance of invasive non-typhoidal Salmonella (iNTS) infections in children.Methods A retrospective study was conducted from January 2018 to December 2022 at two large teaching hospitals: Zhejiang University School of Medicine Children’s Hospital (ZCH) and Children’s Hospital of Soochow University (SCH). Medical records of culture-confirmed iNTS cases were reviewed, and a standardized case report form was used to collect demographic, clinical, and microbiological data.Results A total of 109 cases of iNTS infection were included, with 40 cases from SCH and 69 cases from ZCH. 71 cases (65.1%) were boys.. Infants under 1 year old accounted for 30.3% of the cases. Among the cases, 38 cases (34.9%) had underlying diseases, mainly tumors (55.3%,21/38). The most common sites of infection were the bloodstream (84.4%) and bones and joints (12.8%). The most common serogroups were B (36.8%), C (44.7%) and D (38.2%). The overall resistance rate of ampicillin was 53.6%, ceftriaxone resistance rate was 17.8%, and carbapenem resistance rate was 0%. Seasonal trends indicated higher incidence rates during the summer.Conclusion iNTS infections in children primarily affect the bloodstream and bones/joints, with a significant proportion of cases in those with underlying medical conditions. Ceftriaxone remains the first-line antibiotic, but increasing resistance highlights the need for vigilant antimicrobial stewardship. Carbapenems can be considered as second-line antibiotics in severe cases. Further studies are needed to understand the molecular characteristics and improve treatment strategies for iNTS infections in pediatric patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Committee of the Children's Hospital affiliated to Zhejiang University School of MedicineI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.